Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Sees Large Growth in Short Interest

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) saw a significant growth in short interest in February. As of February 27th, there was short interest totaling 101,072 shares, a growth of 98.9% from the February 12th total of 50,818 shares. Based on an average daily volume of 81,504 shares, the short-interest ratio is presently 1.2 days. Approximately 0.3% of the company’s shares are sold short. Approximately 0.3% of the company’s shares are sold short. Based on an average daily volume of 81,504 shares, the short-interest ratio is presently 1.2 days.

Brainsway Stock Down 1.0%

BWAY stock traded down $0.14 during midday trading on Thursday, hitting $13.64. The company’s stock had a trading volume of 227,078 shares, compared to its average volume of 216,917. The firm has a 50-day simple moving average of $11.96 and a 200-day simple moving average of $9.45. The firm has a market capitalization of $534.76 million, a P/E ratio of 90.91 and a beta of 1.20. Brainsway has a 52-week low of $3.92 and a 52-week high of $14.65.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings data on Wednesday, March 11th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $14.55 million for the quarter, compared to analyst estimates of $14.02 million. Brainsway had a return on equity of 9.46% and a net margin of 12.73%. On average, sell-side analysts expect that Brainsway will post 0.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on BWAY shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Brainsway in a research note on Monday, December 29th. Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. HC Wainwright dropped their target price on Brainsway from $30.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Northland Securities set a $15.00 price target on shares of Brainsway in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, Brainsway presently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Hedge Funds Weigh In On Brainsway

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. purchased a new position in shares of Brainsway in the 2nd quarter valued at about $85,000. Bank of America Corp DE purchased a new stake in shares of Brainsway during the third quarter worth approximately $107,000. Royal Bank of Canada raised its holdings in Brainsway by 1,145.9% in the fourth quarter. Royal Bank of Canada now owns 8,410 shares of the company’s stock valued at $160,000 after acquiring an additional 7,735 shares in the last quarter. Centiva Capital LP acquired a new stake in Brainsway in the third quarter valued at approximately $181,000. Finally, NewEdge Advisors LLC lifted its stake in Brainsway by 61.5% in the first quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock worth $188,000 after acquiring an additional 7,549 shares during the last quarter. Hedge funds and other institutional investors own 30.11% of the company’s stock.

Brainsway News Summary

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: Q4 results beat expectations: Brainsway reported $0.14 EPS vs. $0.11 consensus and revenue of $14.55M vs. $14.02M, showing continued growth and a healthy net margin — this is likely supporting the stock despite other headwinds. Q4 & Full-Year Results
• Neutral Sentiment: Analyst action: HC Wainwright cut its price target sharply from $30 to $15 but kept a “Buy” rating — the lower target reduces upside expectations but the buy endorsement provides some support (the new PT implies modest upside from current levels). HC Wainwright Note
• Neutral Sentiment: Earnings call & transcripts posted: investors can review management commentary for detail on drivers and outlook (transcripts available). These documents add transparency and may influence sentiment once parsed. Earnings Call Transcript
• Negative Sentiment: Weak FY2026 revenue guidance: management provided revenue guidance of $51.0M–$52.0M, well below consensus (~$65M). This guidance gap is the primary negative catalyst weighing on the stock. Guidance Coverage
• Negative Sentiment: Analyst estimate trim: Northland Securities lowered its Q1 FY2026 EPS estimate from $0.04 to $0.03, signaling some near-term earnings pressure and lowering short-term expectations. Analyst Estimate Change
• Negative Sentiment: Rising short interest and prior jump in shorts: data showed a meaningful increase in short interest in February (101,072 shares, ~0.3% of shares), which can add selling pressure or volatility if sentiment worsens. Short Interest Data

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.